Filing Flows › Comparisons › PTHS vs CSBR
Pelthos Therapeutics vs Champions Oncology: PTHS and CSBR compared
Pelthos Therapeutics is the larger company: $15.6M of revenue in its latest quarter (Q2 2026) against $15.2M for Champions Oncology (Q1 FY27). Champions Oncology is more profitable, with an operating margin of -2.7% against -111.0%.
Where the money goes: PTHS and CSBR
Pelthos Therapeutics (PTHS) · Q2 2026
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Champions Oncology (CSBR) · Q1 FY27
Champions Oncology, Q1 FY27: revenue $15.2M (+9% year over year), operating margin -2.7%, net loss $426K, operating cash flow −$492K. The chart follows the revenue to costs, profit and cash.
| Pelthos Therapeutics (PTHS) | Champions Oncology (CSBR) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 FY27 |
| Revenue | $15.6M | $15.2M |
| Revenue growth, Y/Y | — | +9% |
| Operating margin | -111.0% | -2.7% |
| Net earnings | −$23.4M | −$426K |
| Net margin | -150.1% | -2.8% |
| Operating cash flow | −$7.7M | −$492K |
Where the revenue comes from
Pelthos Therapeutics
- Net product revenues: $15.4M (99%)
- License and collaboration revenues: $183K (1%)
Champions Oncology
- Pharmacology services: $14.2M (93%)
- TOS data license revenue: $893K (6%)
- Other TOS revenue: $183K (1%)
Questions
Which is bigger, Pelthos Therapeutics or Champions Oncology?
Pelthos Therapeutics is the larger company: $15.6M of revenue in its latest quarter (Q2 2026) against $15.2M for Champions Oncology (Q1 FY27).
Is Pelthos Therapeutics or Champions Oncology growing faster?
Champions Oncology is more profitable, with an operating margin of -2.7% against -111.0%.
More: Pelthos Therapeutics earnings · how Pelthos Therapeutics makes money · Champions Oncology earnings · how Champions Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Sep 11, 2026). Fiscal quarters can end on different dates. Not investment advice.